HIV, progestins, genital epithelial barrier function, and the burden of objectivity

Abstract Contributions from a diverse set of scientific disciplines will be needed to help individuals make fully informed decisions regarding contraceptive choices least likely to promote HIV susceptibility. This commentary recaps contrasting interpretations of results from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial, a study that compared HIV risk in women using the progestin-only injectable contraceptive depot medroxyprogesterone acetate (DMPA) vs. two other contraceptive choices. It also summarizes results from basic and translational research that establish biological plausibility for earlier clinical studies that identified enhanced HIV susceptibility in women using DMPA. Summary sentence Basic and translational research studies provide strong indication that the contraceptive depot medroxyprogesterone acetate weakens genital mucosal barrier function, a vital first-line defense against HIV and other sexually transmitted pathogens.

[1]  B. Kaur,et al.  Norethisterone Enanthate Increases Mouse Susceptibility to Genital Infection with Herpes Simplex Virus Type 2 and HIV Type 1 , 2020, ImmunoHorizons.

[2]  C. Sathyamala.  Depot contraception and HIV: an exercise in obfuscation , 2019, BMJ.

[3]  T. Cherpes,et al.  Depot-medroxyprogesterone acetate reduces genital cell-cell adhesion molecule expression and increases genital herpes simplex virus type 2 infection susceptibility in a dose-dependent fashion. , 2019, Contraception.

[4]  Douglas J. Taylor,et al.  HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial , 2019, The Lancet.

[5]  C. Sathyamala.  In the name of science: Ethical violations in the ECHO randomised trial , 2019, Global public health.

[6]  T. Cherpes,et al.  Levonorgestrel and Female Genital Tract Immunity: Time for a Closer Look. , 2018, The Journal of infectious diseases.

[7]  T. Cherpes,et al.  Exogenous oestrogen inhibits genital transmission of cell‐associated HIV‐1 in DMPA‐treated humanized mice , 2018, Journal of the International AIDS Society.

[8]  J. Turner,et al.  Cell Biology of Tight Junction Barrier Regulation and Mucosal Disease. , 2018, Cold Spring Harbor perspectives in biology.

[9]  Qingfeng Li,et al.  Contraceptive Practice in Sub-Saharan Africa. , 2017, Population and development review.

[10]  T. Cherpes,et al.  HIV and Hormonal Contraception: Bench and Bedside. , 2017, Journal of acquired immune deficiency syndromes.

[11]  K. Curtis,et al.  An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women , 2016, AIDS.

[12]  T. Hope,et al.  Increases in Endogenous or Exogenous Progestins Promote Virus-Target Cell Interactions within the Non-human Primate Female Reproductive Tract , 2016, PLoS pathogens.

[13]  B. Kaur,et al.  Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection , 2016, Mucosal Immunology.

[14]  J. Darroch,et al.  Adding it up: Costs and benefits of meeting the contraceptive needs of adolescents. , 2016 .

[15]  C. Morrison,et al.  Injectable Progestin‐Only Contraception is Associated With Increased Levels of Pro‐Inflammatory Cytokines in the Female Genital Tract , 2015, American journal of reproductive immunology.

[16]  L. Giudice,et al.  Progestin-Containing Contraceptives Alter Expression of Host Defense-Related Genes of the Endometrium and Cervix , 2015, Reproductive Sciences.

[17]  K. Green,et al.  Desmosomes: regulators of cellular signaling and adhesion in epidermal health and disease. , 2014, Cold Spring Harbor perspectives in medicine.

[18]  K. Natsuga.  Epidermal barriers. , 2014, Cold Spring Harbor perspectives in medicine.

[19]  T. Hope,et al.  Defining the Interaction of HIV-1 with the Mucosal Barriers of the Female Reproductive Tract , 2013, Journal of Virology.

[20]  Eva Hartlieb,et al.  Desmoglein 2 Is Less Important than Desmoglein 3 for Keratinocyte Cohesion , 2013, PloS one.

[21]  T. Hallett,et al.  Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk , 2013, AIDS.

[22]  K. Green,et al.  Structure, function, and regulation of desmosomes. , 2013, Progress in molecular biology and translational science.

[23]  J. Ross,et al.  Increased use of injectable contraception in sub-Saharan Africa. , 2012, African journal of reproductive health.

[24]  D. Hubacher.  Use of hormonal contraceptives and risk of HIV-1 transmission. , 2012, The Lancet. Infectious diseases.

[25]  T. Hope,et al.  Expression of Structural Proteins in Human Female and Male Genital Epithelia and Implications for Sexually Transmitted Infections1 , 2012, Biology of reproduction.

[26]  J. Shelton.  Use of hormonal contraceptives and risk of HIV-1 transmission. , 2012, The Lancet. Infectious diseases.

[27]  J. Baeten,et al.  Use of hormonal contraceptives and risk of HIV-1 transmission : a prospective cohort study , 2011 .

[28]  Kathleen J. Green,et al.  Intercellular junction assembly, dynamics, and homeostasis. , 2010, Cold Spring Harbor perspectives in biology.

[29]  A. Kowalczyk,et al.  The desmosome. , 2009, Cold Spring Harbor perspectives in biology.

[30]  K. Green,et al.  Desmosomes: new perspectives on a classic. , 2007, The Journal of investigative dermatology.

[31]  P. Choyke,et al.  Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan , 2007, Nature Medicine.

[32]  S. Morrison,et al.  A Predominant Role for Antibody in Acquired Immunity to Chlamydial Genital Tract Reinfection1 , 2005, The Journal of Immunology.

[33]  P. Warner.  Concerns regarding design, analysis, and interpretation of the morrison study on hormonal contraceptive use and acquisition of cervical infections. , 2005, Sexually transmitted diseases.

[34]  Z. Klase,et al.  Topical estrogen protects against SIV vaginal transmission without evidence of systemic effect , 2004, AIDS.

[35]  K. Whaley,et al.  Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. , 2002, The Journal of clinical investigation.

[36]  P. Marx,et al.  Estrogen protects against vaginal transmission of simian immunodeficiency virus. , 2000, The Journal of infectious diseases.

[37]  D. Ho,et al.  Progesterone implants enhance SIV vaginal transmission and early virus load , 1996, Nature Medicine.

[38]  Global AIDS update. , 1992, World health forum.